EGFR and cancer: Moreover, compound 4g not only exhibited significant cytotoxicity against most of the cancer cell lines, but also showed significant inhibitory activity (IC50 = 40.7 nM) towards EGFR comparable to that of the medicinally important EGFR inhibitor, gefitinib (IC50 = 38.9 nM).